WisdomTree BioRevolution Fund (WDNA) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.69: the stock has moved about 69% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerWisdomTree BioRevolution Fund (WDNA) trades at $22.90. Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for WDNA: WDNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
WisdomTree BioRevolution Fund (WDNA) Financial Services Profile
WisdomTree BioRevolution Fund (WDNA) offers investors targeted exposure to global companies poised to benefit from advancements in genetics and biotechnology. Employing a representative sampling strategy, the fund aims to replicate the performance of its underlying index, providing a focused investment vehicle within the asset management sector for those seeking to capitalize on bio-revolution trends.
What Is the Investment Thesis for WDNA?
WDNA presents a focused investment opportunity for those seeking exposure to the rapidly evolving genetics and biotechnology landscape. The fund's representative sampling strategy offers an efficient way to track the performance of its underlying index, providing targeted access to companies expected to be significantly impacted by advancements in the sector. With a beta of 1.69, the fund demonstrates higher volatility compared to the broader market, which could lead to potentially higher returns. The absence of a dividend yield reflects the fund's focus on growth-oriented companies within the bio-revolution space. The key value driver is the continued innovation and adoption of genetic and biotechnological advancements across various industries. Upcoming catalysts include further breakthroughs in gene editing technologies and increased investment in personalized medicine, which could drive growth for companies within the fund's portfolio.
Based on FMP financials and quantitative analysis
WDNA Key Highlights
WDNA offers targeted exposure to the bio-revolution sector, focusing on companies expected to be significantly transformed by advancements in genetics and biotechnology.
- The fund employs a representative sampling strategy, aiming to replicate the risk and return characteristics of its underlying index.
- WDNA is a non-diversified fund, which may result in higher volatility compared to more broadly diversified investment options.
- The fund's beta of 1.69 indicates a higher sensitivity to market movements compared to the overall market.
- WDNA does not offer a dividend yield, reflecting its focus on growth-oriented companies within the bio-revolution space.
Who Are WDNA's Competitors?
WDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BWET Breakwave Tanker Shipping ETF | $960.00 | +1.11% | $127M | — |
| BLK BlackRock, Inc. | $1069.63 | -0.91% | $166B | 52 5-pillar |
| BX Blackstone Inc. | $111.80 | -1.38% | $135B | 69 5-pillar |
| APOS Apollo Global Management, Inc. | $25.43 | -0.66% | $74.6B | 56 5-pillar |
| BAM Brookfield Asset Management | $44.50 | -1.57% | $71.1B | 57 5-pillar |
| AMP Ameriprise Financial, Inc. | $490.46 | -1.24% | $44.1B | 78 5-pillar |
| ARES Ares Management Corporation | $115.75 | -1.69% | $38.0B | 57 5-pillar |
| TROW T. Rowe Price Group, Inc. | $104.07 | +0.45% | $22.3B | 80 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WDNA's Key Strengths?
Targeted exposure to the high-growth bio-revolution sector.
- Efficient tracking of its underlying index through representative sampling.
- WisdomTree's established brand and expertise in ETF management.
What Are WDNA's Weaknesses?
Non-diversified nature may lead to higher volatility.
- Reliance on the performance of a specific sector.
- Potential for higher expense ratios compared to broad-based ETFs.
What Are the Key Risks for WDNA?
Regulatory hurdles and changes in government policies impacting the biotechnology sector.
- Clinical trial failures and setbacks in drug development.
- Ethical concerns and public perception regarding gene editing and genetic engineering.
- Economic downturns affecting investment in research and development.
What Are WDNA's Competitive Advantages?
- Specialized Focus: WDNA's focus on the bio-revolution sector provides a unique investment opportunity.
- Representative Sampling Strategy: The fund's approach offers efficient tracking of its underlying index.
- WisdomTree Brand: WisdomTree's reputation and expertise in ETF management provide a competitive advantage.
What Does WDNA Do?
WisdomTree BioRevolution Fund (WDNA) is a specialized, non-diversified exchange-traded fund (ETF) designed to capture the growth potential of companies at the forefront of the genetics and biotechnology revolution. The fund operates under a representative sampling strategy, which involves investing in a carefully selected subset of securities within its benchmark index. This approach aims to replicate the overall risk, return, and characteristics of the entire index, providing investors with a cost-effective and efficient way to access this dynamic sector. The fund focuses on companies that are expected to experience significant transformation due to advancements in genetics and biotechnology. By concentrating its investments in this specific area, WDNA offers a targeted investment vehicle for those seeking exposure to the potential upside of the bio-revolution. The fund's non-diversified nature means that it may be subject to greater volatility than more broadly diversified funds, but it also offers the potential for higher returns if the targeted sector performs well. WisdomTree, as the fund's sponsor, brings its expertise in developing and managing innovative ETFs to the bio-revolution space.
What Products and Services Does WDNA Offer?
- Invests in equity securities of exchange-listed companies globally.
- Focuses on companies expected to be significantly transformed by advancements in genetics and biotechnology.
- Employs a representative sampling strategy to track its index.
- Offers investors exposure to the bio-revolution sector.
- Operates as a non-diversified fund.
- Aims to replicate the risk, return, and other characteristics of its underlying index.
How Does WDNA Make Money?
- Generates revenue through management fees charged to investors.
- Tracks a specific index focused on companies in the bio-revolution sector.
- Utilizes a representative sampling strategy to achieve its investment objective.
What Industry Does WDNA Operate In?
The asset management industry is undergoing significant transformation, driven by technological advancements, changing investor preferences, and increasing regulatory scrutiny. ETFs like WDNA are gaining popularity due to their transparency, cost-effectiveness, and targeted investment strategies. The bio-revolution sector is experiencing rapid growth, fueled by breakthroughs in genetics, biotechnology, and personalized medicine. WDNA competes with other specialized ETFs and mutual funds that focus on healthcare, biotechnology, and genomics. The competitive landscape includes both broad-based healthcare funds and more narrowly focused funds targeting specific areas within the bio-revolution space. These funds include BWET, DESK, EGLE, FGSI, and JETD.
Who Are WDNA's Key Customers?
- Individual investors seeking exposure to the bio-revolution sector.
- Institutional investors looking for targeted investment strategies.
- Financial advisors seeking specialized investment products for their clients.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 43 snapshots
| 2026-08-23 | 47 |
| 2026-08-31 | 47 |
| 2026-09-08 | 47 |
| 2026-09-16 | 47 |
| 2026-09-24 | 47 |
| 2026-10-04 | 47 |
| 2026-10-06 | 47 |
What changed?
The score has stayed at 47.
Over the same 30 days the stock moved +5.5%.
WDNA Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the high-growth bio-revolution sector.
- Efficient tracking of its underlying index through representative sampling.
- WisdomTree's established brand and expertise in ETF management.
- Ongoing: Advancements in gene editing technologies, such as CRISPR-Cas9, leading to new therapeutic applications.
Bear Case
- Non-diversified nature may lead to higher volatility.
- Reliance on the performance of a specific sector.
- Potential for higher expense ratios compared to broad-based ETFs.
- Potential: Regulatory hurdles and changes in government policies impacting the biotechnology sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
WDNA Latest News
-
What’s Going On With Tempus AI Stock on Monday?
benzinga · Aug 24, 2026
WDNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for WDNA.
Price Targets
Wall Street price target analysis for WDNA.
WDNA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for WDNA; grades run from A+ (80-100) to F (below 30).
WDNA Financials Stock FAQ
What are the main risks for WDNA?
As a non-diversified fund focused on the bio-revolution sector, WDNA faces several risks. Regulatory changes impacting the biotechnology and healthcare industries could significantly affect the performance of companies within the fund's portfolio. Clinical trial failures and setbacks in drug development are inherent risks in the biotechnology sector.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.